Trial Profile
Safety & Efficacy of Prolonged Physiologic EPO Level Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis Using MDGN201 TARGTEPO
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs MDGN 201 (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Medgenics
- 05 Jun 2017 Status changed from completed to discontinued.
- 26 Sep 2016 Status changed from active, no longer recruiting to completed.
- 21 Apr 2016 Planned End Date changed from 1 Sep 2017 to 1 Sep 2016.